The partnership further expands Elligo’s growing ‘Research Ready’ site network. The company earlier this year raised $20m in Series C funding to support the company’s goal of connecting physicians and their patients to clinical trials.
“This partnership bridges real world health care needs with the ever-increasing need for patient participation in clinical research,” said Eli Alford, vice president, global operations - research operations, Elligo Health Research.
“Uniquely, it brings innovative treatments directly to patients – through their trusted physician – effectively putting them at the center of the process, making participation convenient and comfortable, and ultimately increasing study enrollment and retention rates,” he told us.
Jack Nathan Health CEO George Barakat said the biggest benefit is to the patients, as the partnership improves access to clinical trials for two million patients annually at the clinic.
“It makes participating in research as care for their condition convenient and cost-effective,” Barakat told us.
“Beyond the patient benefits, JNH will have the opportunity to enhance its engagement and relationship with its patients by expanding its research capabilities without investing in a dedicated department,” he added. “The partnership will also help Elligo fulfill its mission to expand and diversify the patient pool and help sponsors bring better-quality products to market faster.”
